Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arturo Cesaro

Showing results (1-10 of 146) with videos related to

Pageof 15
Sort By:
European Journal of Preventive Cardiology|April 22, 2020
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approachPaolo Calabrò, Arturo Cesaro
Journal of Cardiovascular Medicine (Hagerstown, Md.)|August 3, 2020
Coronary stent thickness: thinner is (always) better for all lesions?Arturo Cesaro, Paolo Calabrò
Biomedicines|November 27, 2025
Feature Reviews in Cardiovascular DiseasesArturo Cesaro, Serafino Fazio
European Journal of Preventive Cardiology|August 26, 2025
Weight for rhythm: is the evidence for atrial fibrillation risk with semaglutide still premature?: replyArturo Cesaro, Paolo Calabrò
Circulation|July 11, 2018
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)"Paolo Calabrò, Felice Gragnano, Arturo Cesaro
Atherosclerosis|April 23, 2026
Hypertension, smoking and adiposity: old enemies, new priorities in FHArturo Cesaro, Paolo Calabrò, Stefano Romeo
Current Vascular Pharmacology|April 15, 2022
Antithrombotic Therapy After TAVI: Evidence, Discordance, and Clinical ImplicationsFelice Gragnano, Arturo Cesaro, Paolo Calabrò
Journal of Clinical Medicine|April 12, 2025
Do Beta-Blockers Really Matter in Patients with Myocardial Infarction Without Left Ventricular Systolic Dysfunction? Comment on Sabina et al. Beta-Blockers in Patients with Myocardial Infarction and Preserved Left Ventricular Ejection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>J. Clin. Med</i>. 2025, <i>14</i>, 150Vincenzo Acerbo, Arturo Cesaro, Paolo Calabrò
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|May 4, 2021
Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the targetArturo Cesaro, Carmine Riccio, Paolo Calabrò
European Journal of Preventive Cardiology|May 19, 2025
Reply to "Oral Formulation and SGLT2i Interaction: Key Nuances in Semaglutide's Effect on Atrial Fibrillation"Arturo Cesaro, Vincenzo Acerbo, Paolo Calabrò
Pageof 15

Showing results (1-10 of 146) with videos related to

Sort By:
Pageof 15
European Journal of Preventive Cardiology|April 22, 2020
Cardiac involvement in systemic sclerosis: 'early diagnosis-early management' approachPaolo Calabrò, Arturo Cesaro
Journal of Cardiovascular Medicine (Hagerstown, Md.)|August 3, 2020
Coronary stent thickness: thinner is (always) better for all lesions?Arturo Cesaro, Paolo Calabrò
Biomedicines|November 27, 2025
Feature Reviews in Cardiovascular DiseasesArturo Cesaro, Serafino Fazio
European Journal of Preventive Cardiology|August 26, 2025
Weight for rhythm: is the evidence for atrial fibrillation risk with semaglutide still premature?: replyArturo Cesaro, Paolo Calabrò
Circulation|July 11, 2018
Letter by Calabrò et al Regarding Article, "Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)"Paolo Calabrò, Felice Gragnano, Arturo Cesaro
Atherosclerosis|April 23, 2026
Hypertension, smoking and adiposity: old enemies, new priorities in FHArturo Cesaro, Paolo Calabrò, Stefano Romeo
Current Vascular Pharmacology|April 15, 2022
Antithrombotic Therapy After TAVI: Evidence, Discordance, and Clinical ImplicationsFelice Gragnano, Arturo Cesaro, Paolo Calabrò
Journal of Clinical Medicine|April 12, 2025
Do Beta-Blockers Really Matter in Patients with Myocardial Infarction Without Left Ventricular Systolic Dysfunction? Comment on Sabina et al. Beta-Blockers in Patients with Myocardial Infarction and Preserved Left Ventricular Ejection: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>J. Clin. Med</i>. 2025, <i>14</i>, 150Vincenzo Acerbo, Arturo Cesaro, Paolo Calabrò
Monaldi Archives for Chest Disease = Archivio Monaldi Per Le Malattie Del Torace|May 4, 2021
Lipid-lowering therapy in high cardiovascular risk patients during COVID-19 pandemic: keep focused on the targetArturo Cesaro, Carmine Riccio, Paolo Calabrò
European Journal of Preventive Cardiology|May 19, 2025
Reply to "Oral Formulation and SGLT2i Interaction: Key Nuances in Semaglutide's Effect on Atrial Fibrillation"Arturo Cesaro, Vincenzo Acerbo, Paolo Calabrò
Pageof 15